Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
Finding the right balance between price and quality can challenge even the most skilled investors. Luckily for you, we started StockStory to help you identify the real opportunities. Keeping that in mind, here are three high-flying stocks where the price is not right and some other investments you should look into instead.
Keysight (KEYS)
Forward P/E Ratio: 31.4x
Spun off from Hewlett-Packard in 2014, Keysight (NYSE: KEYS) offers electronic measurement products for use in various sectors.
Why Are We Wary of KEYS?
- 3.1% annual revenue growth over the last two years was slower than its industrials peers
- Falling earnings per share over the last two years has some investors worried as stock prices ultimately follow EPS over the long term
- Waning returns on capital imply its previous profit engines are losing steam
Keysight is trading at $286.50 per share, or 31.4x forward P/E. To fully understand why you should be careful with KEYS, check out our full research report (it’s free).
Moog (MOG.A)
Forward P/E Ratio: 32.9x
Responsible for the flight control actuation system integrated in the B-2 stealth bomber, Moog (NYSE: MOG.A) provides precision motion control solutions used in aerospace and defense applications
Why Do We Think Twice About MOG.A?
- Annual revenue growth of 4.9% over the last five years was below our standards for the industrials sector
- Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 6.6 percentage points
- Underwhelming 8.1% return on capital reflects management’s difficulties in finding profitable growth opportunities
At $308.25 per share, Moog trades at 32.9x forward P/E. Dive into our free research report to see why there are better opportunities than MOG.A.
West Pharmaceutical Services (WST)
Forward P/E Ratio: 29.9x
Founded in 1923 and serving as a critical link in the pharmaceutical supply chain, West Pharmaceutical Services (NYSE: WST) manufactures specialized packaging, containment systems, and delivery devices for injectable drugs and healthcare products.
Why Are We Cautious About WST?
- 2.1% annual revenue growth over the last two years was slower than its healthcare peers
- Efficiency has decreased over the last five years as its adjusted operating margin fell by 6.7 percentage points
- Waning returns on capital imply its previous profit engines are losing steam
West Pharmaceutical Services’s stock price of $238.92 implies a valuation ratio of 29.9x forward P/E. Read our free research report to see why you should think twice about including WST in your portfolio.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
